AstraZeneca PLC AZN

AstraZeneca PLC (AstraZeneca) es una empresa biofarmacéutica centrada en el paciente. La compañía se enfoca en el descubrimiento y desarrollo, fabricación y comercialización de medicamentos con receta, principalmente para el tratamiento de enfermedades. La compañía se centra en tres áreas terapéuticas principales: Oncología; Cardiovascular, Renal y Metabolismo, y Respiratorio e Inmunología. Su cartera de productos en desarrollo forma un sólido portafolio de terapias en diferentes etapas de desarrollo clínico. La compañía tiene acceso a tecnologías, tanto internamente como a través de sus diversas colaboraciones. Sus tecnologías incluyen la tecnología de tubos acústicos, imágenes moleculares avanzadas, microscopía crioelectrónica (cryo-EM), genómica funcional, multi-ómicas y AstraZeneca iLab. La tecnología de tubos acústicos de la compañía le ayuda a manejar y procesar millones de compuestos para el cribado biológico. Su AstraZeneca iLab es su prototipo de un laboratorio automatizado de química medicinal.

AZN hizo una agrupación de acciones (split inverso) de 1:2 el 2 de febrero de 2026: cada 2 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 2 oct

  Europe Cancer Metabolism Based Therapeutics Market Forecast to 2035 by Modality, Route, Indication, and Therapy Sales | 25.3% CAGR Drives an $8.54 Billion Opportunity

  Europe's cancer metabolism-based therapeutics market is projected to grow from $1.12 billion in 2026 to $8.54 billion by 2035, representing a 25.3% CAGR. Growth is driven by Europe's high cancer burden, advances in molecular profiling, precision oncology adoption, and regulatory validation. Small molecules and oral administration routes dominate, with breast cancer and non-small cell lung cancer as leading indications. Key players include AstraZeneca, Bayer, Novartis, Roche, and Servier.

  

• GlobeNewswire Inc. 1 oct

  DaltonTx, the decision engine for drug discovery, launches advanced AI-powered antibody discovery platform

  DaltonTx announced the launch of advanced antibody discovery capabilities within its Dalton platform, which integrates AI models for antibody design, structure prediction and validation. The platform can evaluate millions of antibody sequences and help researchers identify promising candidates more efficiently by combining AI outputs with experimental data and expert judgment.

  

• GlobeNewswire Inc. 30 sept

  Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - 2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities

  The bone metastasis in solid tumors market is expected to expand from 2026-2036 across seven major markets, driven by rising cancer survival rates, improved diagnostics, and growing demand for targeted therapies and radiopharmaceuticals. The market is characterized by established treatments like denosumab and zoledronic acid, with emerging therapies including cabozantinib and radioligand treatments. Key unmet needs include limited disease-modifying therapies, persistent skeletal complications, and lack of validated biomarkers for treatment selection.

  

• Zacks Investment Research 29 sept

  Astrazeneca (AZN) Registers a Bigger Fall Than the Market: Important Facts to Note

  Astrazeneca stock fell 1.17% on September 29, 2026, underperforming the S&P 500's 0.17% decline. The pharmaceutical company is expected to report earnings on October 30, 2026, with predicted EPS of $2.17 (down 8.82% YoY) and revenue of $16.07 billion (up 5.82% YoY). AZN holds a Zacks Rank #3 (Hold) with a Forward P/E of 17.73, trading at a discount to its industry average of 25.2.

  

• GlobeNewswire Inc. 28 sept

  HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

  HUTCHMED announced that AstraZeneca has submitted a New Drug Application (NDA) to the FDA for ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) to treat patients with MET-driven EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy. The submission is supported by the SAFFRON Phase III trial, which demonstrated statistically significant improvements in progression-free survival and overall survival compared to platinum-based chemotherapy.